JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage'
JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage'
JPMorgan Chase & Co.'s (NYSE:JPM) asset management division has reportedly secured over $500 million for a biotech venture capital fund focusing on weight-loss drugs, targeting the booming sector of the healthcare industry.
摩根大通（NYSE：JPM）的資產管理部門據報道已爲一家專注於減肥藥的創投基金獲得了超過5億美元的資金，針對醫療保健行業蓬勃發展的板塊。
The fund concluded this month, and according to Steve Squinto, the chief investment officer of the unit's life-sciences team, "the top three choices are obesity, obesity, and obesity," Bloomberg reported, citing an interview with Squinto.
基金於本月結束，該部門的生命科學團隊首席投資官Steve Squinto在接受採訪時稱：“前三個選擇都是肥胖，肥胖和肥胖”，彭博報道。
Glucagon-like peptide-1 or GLP-1, commonly referred to as weight-loss drugs, "are all the rage," Squinto stated, emphasizing that the field is "wide open," the report added.
Squinto表示，類胰高血糖素-1或GLP-1，通常被稱爲減肥藥，“風靡一時”，他強調該領域“充滿機遇”，報告補充說。
Check This Out: ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
查看這個:etf高水平押注減肥藥，但業內人士質疑長期潛力
"This has the opportunity to be a pivotal moment in the pharmaceutical industry," Bloomberg added.
彭博補充說：“這有機會成爲製藥業的關鍵時刻”。
The new class of weight-loss drugs has exploded in popularity in recent months, with ballooning demand causing shortages.
最近幾個月，新型減肥藥類別在市場上迅速擴張，需求激增導致短缺。
Novo Nordisk (NYSE:NVO) and Eli Lilly And Company (NYSE:LLY) currently command the field.
目前，諾和諾德（NYSE：NVO）和禮來公司（NYSE：LLY）主宰這個市場。
Also See: Ozempic, Wegovy Create Domino Effect As New Products Emerge Across Industries To Capture New Consumer Habits
另請參閱：隨着新產品湧現，跨行業抓住新的消費習慣，Ozempic，Wegovy創造多米諾骨牌效應
"It's very unlikely that the future of obesity treatment will be dominated by a stable duopoly," Gaurav Gupta, the fund's managing partner, said in an interview with Bloomberg. "There will be significant winners."
該基金的管理合夥人Gaurav Gupta在接受彭博採訪時表示：“將來肥胖症治療的趨勢非常不可能被一個穩定的雙頭壟斷所主導”，“將會有重要的贏家。”
In late 2022, JPMorgan, the largest U.S. bank, recruited Squinto and Gupta as its $3.6 trillion asset management business initiated the life sciences team. This group, comprising seven members, operates within the bank's private capital business, a segment of its broader alternatives division.
2022年末，美國最大的銀行摩根大通招募了Squinto和Gupta，啓動了生命科學團隊，該團隊由7名成員組成，隸屬於該行的私募股本業務，這是該行更廣泛的替代產品部門的一個組成部分。
Apart from weight-loss treatments, the fund will invest in sectors like oncology and immunology.
除了減肥治療，該基金還將投資在腫瘤學和免疫學等板塊。
Price Action: JPM shares are trading higher by 0.32% to $192.14 premarket at last check Thursday.
股價表現：截至上週四最後一次檢查，JPM股價上漲0.32％，至192.14美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明說明：此內容部分使用人工智能工具製作，並由Benzinga編輯進行了審核和發佈。
Image: Pixabay
圖片：Pixabay
譯文內容由第三人軟體翻譯。